The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The finance will happen, the govt is notoriously slow but will ultimately help the company attain the finance. So no RNS @ 7am, just the dreaded post close one to navigate now.
Buy button for sub 6p buys at the ready ? Hopefully an April 30p trim instead.
Happy Easter.
JD. is in a great position for a full recovery and there is relief that there was little new bad news. Q1 news not really a surprise.
Buying any decent dip as this will fluctuate in the 95- 130 trading range until the Summer.
GL all.
Given this, Q1 is likely to be the softest LFL period of the year and H2 is likely to be stronger than H1. In addition, cost inflation remains elevated, particularly labour, and we will continue to invest in our infrastructure in FY25 to deliver our long-term growth plan.
Sorted should be a boost
+25m ANNUALLY
-7/8m costs 2024/29
Savings Net £16/17m - reinvest in business growth £10
WIll there be a special dividend ?
RECURRING annualised BENEFIT to Adjusted EBITDA of approximately £25 million from 2025 onwards.
Expects to incur net one-off cash costs of approximately £40 million in relation to the exit of the US, inclusive of the brand licence termination fee already announced, with such payments occurring from 2024 until 2029.
Https://www.londonstockexchange.com/news-article/888/sale-of-us-b2c-assets-to-hard-rock-digital/16399014
888 Holdings Plc
("888" or "the Group")
Sale of US B2C assets to Hard Rock Digital
888 (LSE: 888), one of the world's leading betting and gaming companies with internationally renowned brands including William Hill, 888 and Mr Green, today announces the conclusion of its strategic review of US B2C operations. As a result of the review the Group has agreed the sale of selected assets to Hard Rock Digital ("HRD"), completion of which is conditional upon, amongst other items, relevant regulatory approvals. It is expected that the disposal will be completed in a number of phases, with final completion expected in Q4 2024.
The Group has commenced a controlled exit of its remaining US B2C operations, with the intention of fully ceasing operations by the end of 2024, subject to regulatory approvals and process. The exit of US B2C operations is expected to realise a recurring annualised benefit to Adjusted EBITDA of approximately £25 million from 2025 onwards. The Group intends to reinvest approximately £10 million of these savings into growth and value creation initiatives.
The combined net impact of the sale and exit of US B2C were already incorporated into the financial targets that the Group announced on 26 March 2024. The Group currently expects to incur net one-off cash costs of approximately £40 million in relation to the exit of the US, inclusive of the brand licence termination fee already announced, with such payments occurring from 2024 until 2029.
When you see the Times today you hold your nose and buy. The take out price will be north of 41p for sure.
The false start on Monday, not too longer to wait.
Should propel higher
Confident presentation. Right team right time and right approach.
Looking forward to seeing and investing in their new products.
Although I do think the shares at the current prices are going to reward more than the 5% rates in the bank.
This could be up by 20% alone in the next fortnight.
The bottom is firmly in.
Https://www.proactiveinvestors.co.uk/companies/news/1044141/vanquis-banking-group-upgraded-but-risks-remain-says-investment-bank-1044141.html
Panmure Gordon has reversed its November downgrade of Vanquis Banking Group PLC (LSE:VANQ) on the back of the lender's prelims - although the stockbroker recognises that 'risks remain'.
It has moved 'buy' from 'hold' on shares in the credit cards and loans group, which it values at 75p - around a third more than the stock is worth today at 56p (up 8.5%).
"What is more important by far is the company’s objective of getting back to earning a mid-teens RoTE [return on tangible equity] by 2026," said Panmure in a note to clients.
"We believe that this equates to a business making around £100m of adjusted PBT [profit before tax] and close to 30p of adjusted earnings per share.
"Risks remain high – there are the invidious attentions of a CMC to negotiate – but a potential PER [price-to-earnings ratio] of under two times suggests also that there is more than enough opportunity to offset that risk."
Not surprised after JW showboating. Even if he offered to do it for free, I too would have looked elsewhere.
JW should concentrate on the finance deal in place and removing the negative audit statements.
Long overdue John.
Indeed they have. Always a good sign.
Not pocket money either. Pity they missed the 720p price :)
27-Mar-24 25-Mar-24 Buy Shriti Vadera 771.89 GBX 50,000
27-Mar-24 27-Mar-24 Buy Anil Wadhwani 752.84 GBX 57,435
27-Mar-24 27-Mar-24 Buy Anil Wadhwani 74.94 HKD 11,700
1
Light at the end of the tunnel - FSA progressing to pass FSA costs of unmeritous claims back to the Claim companies. Moving with pace
2 Making an unmeritous claim can effect the claimants credit rating, the CMCs do not care but the claimant will.
Fight back.